Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of trastuzumab and pertuzumab combination therapy for HER2-amplified advanced solid tumors
jRCTs031220444Active, not recruiting
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab and pertuzumab in Nonhematologic neoplasms. Primary endpoint: Overall survival. Started Dec 2022; status: active, not recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCTs031220444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220444.